Tandem autologous-allo-SCT is feasible in patients with high-risk relapsed non-Hodgkin's lymphoma

R. Crocchiolo, L. Castagna, S. Fürst, J. El-Cheikh, C. Faucher, C. Oudin, A. Granata, R. Bouabdallah, D. Coso, C. Chabannon, M. Balzarotti, A. Santoro, D. Blaise

Research output: Contribution to journalArticle

Abstract

Allo-SCT is used to exploit GVL effect in high-risk relapsed non-Hodgkin's lymphoma (NHL). Here, we retrospectively analyzed 34 high-risk NHL patients who underwent auto-SCT followed closely by reduced-intensity allo-SCT ('tandem auto-allo') from January 2002 to November 2010. The search for an allogeneic donor was started at the beginning of salvage regimen. Median patients' age was 47 (27-68) years; histotypes were: diffuse large B-cell n=5, follicular n=14, transformed follicular n=4, mantle-cell n=5, plasmocytoid lymphoma n=1, anaplastic large T-cell n=2, peripheral T-cell n=3. Donors were HLA-identical siblings (n=29) or 10/10-matched unrelated individuals (n=5). Median interval between auto-SCT and allo-SCT was 77 days (36-197). At a median follow-up of 46 (8-108) months since allo-SCT, 5-year OS is 77% (61-93) and PFS is 68% (51-85). Disease relapse or progression occurred in six patients, 100-day TRM was 0%, 2-year TRM incidence was 6%. In conclusion, tandem transplantation is feasible in high-risk NHL patients having a HLA-identical donor. This approach could represent a suitable therapeutic option for those patients with high-risk NHL potentially benefitting from further therapy after auto-SCT. Donor searches should be started promptly whenever such an approach is chosen.

Original languageEnglish
Pages (from-to)249-252
Number of pages4
JournalBone Marrow Transplantation
Volume48
Issue number2
DOIs
Publication statusPublished - Feb 2013

Keywords

  • allogeneic
  • autologous
  • non-Hodgkin's lymphoma
  • SCT
  • tandem

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Fingerprint Dive into the research topics of 'Tandem autologous-allo-SCT is feasible in patients with high-risk relapsed non-Hodgkin's lymphoma'. Together they form a unique fingerprint.

  • Cite this

    Crocchiolo, R., Castagna, L., Fürst, S., El-Cheikh, J., Faucher, C., Oudin, C., Granata, A., Bouabdallah, R., Coso, D., Chabannon, C., Balzarotti, M., Santoro, A., & Blaise, D. (2013). Tandem autologous-allo-SCT is feasible in patients with high-risk relapsed non-Hodgkin's lymphoma. Bone Marrow Transplantation, 48(2), 249-252. https://doi.org/10.1038/bmt.2012.116